What is PEN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 12.64B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PEN?

P/E (TTM) is 78.72 and 52-week range is $221.26 to $362.41 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PEN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PEN?

The company profile lists revenue (TTM) near $1.50B, net income (TTM) near $160M, EPS (TTM) near $4.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Penumbra Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Alameda, California, US, 39.3M shares outstanding, ISIN US70975L1070 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Penumbra Inc (PEN) Stock Analysis, Quote & Company Profile

Free AI scores & summaries library

Penumbra Inc

$PEN

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$320.86

-0.11%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Employees

4,700

Website

www.penumbrainc.com/

IPO

2015-09-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)